Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
Yi Zheng(Second Hospital of Tianjin Medical University), Tong Liu(Second Hospital of Tianjin Medical University), Gary Tse(Observational & Pragmatic Research Institute), Yihong Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Jeffrey Shi Kai Chan(Southlake Regional Health Center), Wenhua Song(Second Hospital of Tianjin Medical University), Yanmin Xu(Second Hospital of Tianjin Medical University), Jun Zhao(Second Hospital of Tianjin Medical University), Zhiqiang Zhao(Second Hospital of Tianjin Medical University), Guangping Li(Qingdao University), Xiaowei Zhang(Second Hospital of Tianjin Medical University), Lili Hong(Tianjin University of Traditional Chinese Medicine), Yuanyuan Wang(Second Hospital of Tianjin Medical University), Ziliang Chen(Guizhou University), Yu Xu(Kunming Medical University), Xuhong Geng(Hebei Medical University)
Cited by 14
Related Papers
Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation
|Journal of the American College of Cardiology|2019|494
The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy
|Nature Medicine|2016|393
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
|The Lancet Diabetes & Endocrinology|2017|325
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
|Cardiovascular Diabetology|2019|296
General Synthesis of Dual Carbon‐Confined Metal Sulfides Quantum Dots Toward High‐Performance Anodes for Sodium‐Ion Batteries
|Advanced Functional Materials|2017|293